Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.
Josh Carle is the Chief Business Officer of Hinge Bio, a Burlingame, California biotech building multivalent, multispecific antibody therapies on its GEM-DIMER platform. A dealmaker by trade, he has led or advised more than fifty strategic transactions worth over $2 billion in disclosed deal value, moving from Pfizer Oncology and Daiichi Sankyo to immuno-oncology startup Triumvira before joining Hinge Bio in January 2023 to steer its lead lupus program toward the clinic.